igf-1 lr3 what is it RUO Recombinant Human Protein Receptor Grade IGF-1 LR3 For
Description
Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial
Mechanistically, this variant disrupts SP1 transcription factor binding to the JMJD3 promoter, reducing its expression in vascular smooth muscle cells (SMCs)
Release 381 , 113573 (2025) K.W
& Schmidt-Wolf, I
Cancer Cell 42 , 513534 (2024)
